Genmab A/S (OTCMKTS:GNMSF) Shares Gap Up – Still a Buy?

Genmab A/S (OTCMKTS:GNMSF)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $281.06, but opened at $289.85. Genmab A/S shares last traded at $298.38, with a volume of 5 shares changing hands.

Genmab A/S Stock Performance

The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock has a market cap of $18.37 billion, a price-to-earnings ratio of 19.28 and a beta of 0.94. The firm has a fifty day moving average of $289.26 and a 200 day moving average of $305.63.

Genmab A/S (OTCMKTS:GNMSF) last posted its quarterly earnings results on Tuesday, February 17th. The company reported $0.55 EPS for the quarter, missing the consensus estimate of $3.10 by ($2.55). The company had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.05 billion. Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.